Previous 10 | Next 10 |
The packaged-foods sector provided a ray of light for investors on Wednesday despite a slide for the overall markets. The segment bounced back from recent weakness on signs that companies might be starting to catch up to the inflation pressures that have weighed on the group. General Mil...
Having dropped from the lofty heights it reached only a few short months ago, Alector (NASDAQ: ALEC) stock was having another bad day on Wednesday. The biotech's shares were down nearly 17% in mid-afternoon trading following some news from the C-suite. After market hours on Tues...
Gainers: Kadmon (NASDAQ:KDMN) +73%. ICU Medical (NASDAQ:ICUI) +32%. Candel Therapeutics (NASDAQ:CADL) +23%. Globalstar (NYSE:GSAT) +22%. Spectrum Brands (NYSE:SPB) +20%. Vinco Ventures (NASDAQ:BBIG) +19%. WISeKey (NASDAQ:WKEY) +14%. SilverBow (NYSE:SBOW) +16%. Aterian (NASDAQ:ATER) +16%. Gain...
Gainers: Kadmon KDMN +73%, ICU Medical ICUI +32%, Candel Therapeutics CADL +17%, Gain Therapeutics GANX +9%, Concord Medical Services (NYSE:CCM) +9%. Losers: INmune Bio (NASDAQ:INMB) -22%, Inozyme Pharma (NASDAQ:INZY) -19%, Alector A...
Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer Sam Jackson, M.D., MBA, Appointed Interim Chief Medical Officer SOUTH SAN FRANCISCO, California, Sept. 07, 2021 (...
Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer’s Association International Conference (AAIC) Announced global collaboration with GSK to co-develop and co-commercialize progranulin-elevating monoclonal a...
After four back-to-back sessions of gains, the healthcare stocks in the S&P 500 finished ~0.5% higher this week to outperform the ~0.4% loss recorded by the broader index over the past five-day period. A major industry event on Alzheimer’s disease dominated heal...
Abbvie (ABBV -1.5%) has decided to advance a candidate that will target beta-amyloid plaque in the brain as an Alzheimer's treatment, while abandoning ABBV-8E12, a phase 2 asset that was targeting tau, another type of protein. The announcement was made this morning on Abbvie's Q2 earning...
AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients Treatment with AL001 Slowed Clinical Progression by 47% Based on the CDR ® plus NACC FTLD-SB Scale Relative to GENFI2 Matched Control Cohort Consistent Trends toward Normalizati...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...